News

Multiple Sclerosis Patients Show Real Gains from Group Exercise Program

Results from a recent study published in the journal Rehabilitation Research and PracticeĀ showed the positive effects of community exercise programsĀ in multiple sclerosis (MS)Ā patients. Study participants showed physical improvements like higher energy levels and reduced fatigue, psychological benefits from those improvements and from group support and motivation, and…

Microchips May Be New Standard in Multiple Sclerosis Studies

In a new article published in the journal Trends in Biotechnology, Korean researchers suggest that diseases of the central nervous system (CNS) might be better studied using compact, accessible chip technology than in current methods. The report, titled “Central Nervous System and its Disease…

Multiple Sclerosis Therapeutics’ Market Value to Reach $20B by 2024

RnR Market Research, a company offering market research reports on fields that include healthcare, pharmaceutical, technology, energy, and industry, recently publicized a new report on the epidemiology of multiple sclerosis (MS) and a forecast of its therapeutic market value. The report is entitled ā€œEpiCast Report: Multiple Sclerosis – Epidemiology…

Consortium of Multiple Sclerosis Centers (CMSC) Emphasizes the Role of Physicians in MS Medical Treatment Decisions

The Consortium of Multiple Sclerosis Centers (CMSC), an organization for researchers and healthcare professionals committed to multiple sclerosis (MS) care and treatment, has recently issued a position statement claimingĀ that prescribers should have the right to make clinical decisions on the best treatments and medications in each individual MS case.

Neurons in Multiple Sclerosis Patients May be Protected by Vitamin D

A new study from Sweden indicates that vitamin D could help protect nerve cellsĀ (neurons) in multiple sclerosis (MS). The report, titled “Vitamin D and axonal injury in multiple sclerosis,“ was published on October 13, 2015, in the Multiple Sclerosis Journal. Scientists have demonstrated, in…

Biogen’s Investment in Multiple Sclerosis Therapies Reinforced in Company Restructuring

Advancing key medicinal treatments likeĀ TECFIDERA (dimethyl fumarate), the most prescribed oral treatment for multiple sclerosis (MS), is a key focus of a company-wide restructuring recently announced byĀ Biogen, Inc.Ā TECFIDERA has been shown to reduce relapse rates, slow disability progression and the number of brain lesions in patients with relapsing forms…

Generic Form of Glatiramer Acetate Has Equivalent Gene Expression Profile as Teva’s Copaxone

In a recent study entitled ā€œEquivalent Gene Expression Profiles between Glatopaā„¢ and CopaxoneĀ®,ā€ authors determined potential differences in treatment responses by investigating the gene expression profile of two approved treatments for relapsing forms of multiple sclerosis ā€“ Copaxone and Glatopa. Both of these MS therapies are glatiramer…

Teva Pharmaceutical Industries’ COPAXONE 40 mg/mL Three-times-a-week Approved in Russia for Relapsing-Remitting Multiple Sclerosis

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day, recently announced the approval of a Marketing Authorization license (MA) by the Russian Ministry of Health for three-times-per-week COPAXONEĀ®(glatiramer acetate injection) 40 mg/mL, a new dose of COPAXONEĀ®,…

EMD Serono Announces Publication of PRISMS-15 Years Follow-up Study Results on Rebif for Relapsingā€“Remitting Multiple Sclerosis

EMD Serono, the U.S. biopharmaceutical division of Merck KGaA, Darmstadt, Germany, recently announced that the results of the 15 year follow-up trial PRISMS-15 (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) evaluating RebifĀ® (interferon beta-1a), a high-dose, high-frequency interferon beta for the treatment of…

Adamas Reports Walking Improvement in MS Models with ADS-5102 (Amantadine HCl)

Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the companyā€™s product candidate ADS-5102 can be potentially applied as a treatment for multiple sclerosis (MS) symptoms. MS is a chronic, progressive neurodegenerative autoimmune…

The Future of Stem Cell Therapy for Multiple Sclerosis Patients Relies on Clinical Trial Participation

Among the different therapeuticĀ approaches being explored for treating MS,Ā adult stem cell therapy continues to beĀ one of the most discussed and anticipatedĀ in the MS community. ā€œStem cellsā€ ā€” the common term for undifferentiated, self-renewing proliferating cells ā€”Ā are currently being investigated for their ability to treatĀ patients in a wide range of disease…

Study Reports No Influence of Vitamin D Supplementation on Inflammation in Relapsing-Remitting Multiple Sclerosis

A recentĀ study of people with relapsing remittingĀ multiple sclerosis (RRMS) found thatĀ high-dose oral vitamin D3 supplementation did not influence markers of inflammation. Inflammation is a reaction to bodily injury that may be over-activated in people with multiple sclerosis (MS).Ā The article, titled “Vitamin D supplementation and systemic inflammation in…

Prof. Jorge Correale Reviews Environmental Factors Associated with Multiple Sclerosis at ECTRIMS 2015

Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 ā€“ 10, 2015). The first parallel session was entitled ā€œWill MS…